• SCOTT'S WEB LOG  |  TUESDAY, NOVEMBER 9, 2010
    [Biosynthetic Insulin, JDRF] Scott's Web Log: 11/9: D-Blog Day & 6 Things You SHOULD know About.
    Biosynthetic insulin analogues have done absolutely nothing to improve my glycemic control; Id happily trade Levemir for porcine Lente any day, and I had a comparable HbA1c back then, too, plus life was easier and cheaper. But analogues have quadrupled the amount of money that I have to pay for insulin. I have Type 1 diabetes and no matter how much I exercise and how well I diet, I will be dead by tomorrow without an external supply of insulin.
  • SCOTT'S WEB LOG  |  WEDNESDAY, JULY 16, 2008
    [Biosynthetic Insulin, JDRF] Innocent Until Proven Guilty
    One of the key findings was that in type 2 diabetes, beta cell destruction is caused (in part, anyway) because of some insulin molecules produced by the body being slightly deformed due to some type of disruption in the body's natural insulin production process. In other words, the body recognizes that at least some the insulin molecules are imperfect, and responds by sending out the immune system to destroy the "offending" beta cells responsible.
  • SCOTT'S WEB LOG  |  WEDNESDAY, JULY 16, 2008
    [Biosynthetic Insulin, JDRF] Innocent Until Proven Guilty
    One of the key findings was that in type 2 diabetes, beta cell destruction is caused (in part, anyway) because of some insulin molecules produced by the body being slightly deformed due to some type of disruption in the body's natural insulin production process. In other words, the body recognizes that at least some the insulin molecules are imperfect, and responds by sending out the immune system to destroy the "offending" beta cells responsible.
  • SCOTT'S WEB LOG  |  FRIDAY, NOVEMBER 16, 2007
    [Biosynthetic Insulin, JDRF] The Business of Diabetes: Signs Suggest Lilly's Type 1 Diabetes Strategy May Be Evolving
    Since 1923, Eli Lilly and Company's strategy for type 1 diabetes has been fixated on insulin replacement, and more recently, pushing the idea of intensified insulin therapy. Although Lilly's Humalog was the first insulin analog on the market, over the past decade especially, Lilly took its eyes off the ball and lost its position of dominance in the U.S. insulin market back in 1995 to just 43% in 2006 according to data from IMS Health. insulin market.
  • SCOTT'S WEB LOG  |  FRIDAY, NOVEMBER 16, 2007
    [Biosynthetic Insulin, JDRF] The Business of Diabetes: Signs Suggest Lilly's Type 1 Diabetes Strategy May Be Evolving
    Since 1923, Eli Lilly and Company's strategy for type 1 diabetes has been fixated on insulin replacement, and more recently, pushing the idea of intensified insulin therapy. Although Lilly's Humalog was the first insulin analog on the market, over the past decade especially, Lilly took its eyes off the ball and lost its position of dominance in the U.S. insulin market back in 1995 to just 43% in 2006 according to data from IMS Health. insulin market.